Reading the Tea Leaves: Top 10 Enforcement and Regulatory Risks for Device Makers in 2026

Prepare for what’s next in 2026 — join us to get a clear, practical briefing on enforcement priorities and regulatory and compliance risks facing medical device companies in 2026.  We’ll discuss the implications for device companies of recent efforts by the administration to ramp up enforcement around federal health care programs, including the appointment of a former U.S. attorney to the HHS Office of the General Counsel to focus on health care fraud, DOJ’s new division for national fraud enforcement, DOJ’s expanded Health Care Fraud Unit New England Strike Force and the latest on the relaunched DOJ-HHS False Claims Act Working Group.  We’ll also explore tactical compliance and regulatory risk areas facing medical device companies, including arrangements with HCPs and purchasers, Open Payments issues, arrangements with independent sales agents, state law enforcement and compliance issues, trending FDA regulatory areas and other areas. Our goal is to help you look around the corner to see risk areas that could hit your desk in 2026. 

For questions, or for registration information, contact Ella Peek.